FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WEINGARTEN ROBERT N (Last) (First) (Middle) C/O CORTEX PHARMACEUTICALS, INC.					2. Issuer Name and Ticker or Trading Symbol CORTEX PHARMACEUTICALS INC/DE/ CORX 3. Date of Earliest Transaction (Month/Day/Year) 08/18/2015							Officer (six a title					
126 VALLEY ROAD, SUITE C (Street) GLEN ROCK NJ 07452 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indivi	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3)				2. Tra	ransaction 2A Deemed		3. Transacti Code (Ins	r. (4)		(A) or 3, 4 and 5)	5. Amount of 6. Securities For Beneficially Owned on		Form:	irect (I)` ′	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										, or Benefic ble securit	cially Owned	d			<u> </u>		
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following		Ownership Form: Direct (D) or Indirect (I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transacti (Instr. 4)	ion(s)	on(s) 4)		
Common Stock Options (to purchase shares of Common Stock)	\$0.0197	08/18/2015		Λ		10,000,000		(1)	08/18/2022	Common Stock	10,000,000	\$0	10,000,	,000	D		
Common Stock Options (to purchase shares of Common Stock)	\$0.025							(2)	06/30/2022	Common Stock	15,000,000		15,000,	,000	D		
Common Stock Options (to purchase shares of Common	\$0.05							(3)	07/17/2019	Common Stock	5,000,000		5,000,0	000	D		

Explanation of Responses:

- 1. These Common Stock Options vest in four equal installments: 25 percent on December 31, 2015, 25 percent on March 31, 2016, 25 percent on June 30, 2016, and 25 percent on September 30, 2016.
- 2. These Common Stock Options vest in three installments: 50 percent on June 30, 2015, 25 percent on September 30, 2015, and 25 percent on December 31, 2015.
- 3. These Common Stock Options vested in three equal installments on July 17, 2014, September 30, 2014 and December 31, 2014, and are all currently vested and exercisable.

/s/ Robert N. Weingarten 08/20/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).